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Featured Clinical Research
Comparison of Safety and Efficacy of CYPHER® Stent and ENDEAVOR®
Stent in Patients with Acute ST Elevation Myocardial Infarction(STEMI)
undergoing emergency PCI and Analysis of Current Status of Emergency PCI
Green Channel in China
Lefeng Wang, Dapeng Zhang, Xinchun Yang, Yonggui Ge, Hongshi Wang, Weiming
Li, Li Xu, Yu Liu
Background: To compare the Safety and Efficacy of CYPHER® Sirolimus Stent and
ENDEAVOR® Zotarolimus Stent in Patients with Acute STEMI undergoing
emergency PCI, and to analysis Current Status of Emergency PCI Green Channel for
Patiens with STEMI in China.
Methods: 1020 patients were to be randomized, these patients were STEMI within 12
hours preparing emergency PCI, with “De novo”lesions in native coronary arteries,
and informed consent were written. and 145 cases were exclused(14.2%), totally 875
patients entered the study, 449 patients in ENDEAVOR group and 426 patients in
CYPHER group, totally 761 patients (86.9%) with 6-months Clinical follow-up. The
primary endpoints were cardiac mortality, myocardial infarction, and target lesion
revascularization (TLR) at 6 months.
Results: The Baseline Clinical Characteristics and Lesion Characteristics between 2
groups were no significant, Myocardial Infarction at 6 months between 2 groups were
2and 3(P =0.61),Stent Thrombosis at 6 months between 2 groups were both 2 cases(P
=0.96),Stent restenosis at 6 months between 2 groups were 5 and 1(P=0.09),Target
Lesion Revascularization at 6 months at 6 months between 2 groups were 6 and 3(P
=0.35),Cardiac death at 6 months were 12 and 9(P =0.56),Composite MACE at 6
months at 6 months were 20(4.5%)and 15(3.5%),P =0.48. The analysing of Emergency
Green Channel showed that the mean time of door to ballon was 119.2±80.1 minutes
(40~710 min), and only 47.6% patients whose D T B time was less than 90 minutes.
Conclusion: 1. There was no signal differential profile between Cypher and Endeavor
during 6 months in safety and efficacy. The antirestenotic efficacy of Endeavor was
somewhat inferior to the Cypher stent in Patients with STEMI undergoing emergency
PCI at 6-month follow-up. 2.Currently, AMI patients of Chinese first class hospital are
treated delayed seriously. There is still a big gap with PCI Guide which require 90min
from door to balloon.
Long-term Clinical Results from the All-comers LEADERS Trial: 4 Year
Follow-up Data.
Thomas A. Ischinger, Patrick W. Serruys, Marie-Claude Morice, Pawel Buszman,
Axel Linke, Volker Klauss, Diethmar Antoni, Hae Young Sohn, Roberto Corti, Franz
Eberli, William Wijns, Carlo Di Mario, Peter Juni, Stephan Windecker
Background: There is concern of an increased incidence of very late stent thrombosis,
associated with early generation DES potentially related to the durable polymer. The
Biolimus A9™ eluting stent platform (BES) releases biolimus from an abluminal
biodegradable polymer, polylactic acid (PLA), which is fully absorbed after 6-9
months. The LEADERS trial aimed to compare the safety and efficacy of BES with an
established stent platform releasing sirolimus from a durable polymer (SES) in a large
scale, all-comers, non-inferiority trial. The purpose of this presentation is to present the
4- year follow-up data to determine whether there are differences between the
biodegradable BES platform as compared to the durable polymer SES platform.
Methods: LEADERS is a multi-center, randomized, assessor-blind, non-inferiority
trial performed at 10 European sites in an all-comers, “real world” patient population
without limitation with respect to lesion length, number of treated lesions or vessels as
well as clinical indication (chronic stable angina vs. acute coronary syndromes). A total
of 1,707 patients were enrolled and randomly allocated 1:1 to BES or SES. The primary
endpoint was MACE (a composite of cardiac death, MI, or clinically-indicated TVR)
at 9 months. Secondary endpoints include death, cardiac death, MI, ST (ARC defined),
TLR and TVR. All patients are followed up to 5 years.
Results: BES sustained its non-inferiority to SES in terms of the primary endpoint of
MACE up to 4 year follow-up with a trend towards improved outcomes at 4 years
(18.7% for BES vs. 22.6% for SES, RR (95% CI): 0.81 (0.66 to 1.00), p
non-inf<0.0001,psup=0.051). Very late definite stent thrombosis (0.4% for BES vs.
1.8% for SES, RR(95% CI): 0.20 (0.06 to 0.67), psup=0.004) as well as very late
definite/ probable stent thrombosis (0.7% for BES vs. 2.4% for SES, RR (95% CI):
0.29 (0.12 to 0.73), psup=0.005) were less frequent with BES than SES at 4 years. The
4 year outcomes are summarized in table 1.
Conclusion: Our results suggest that BES represents a safe and effective alternative to
SES with robust clinical results up to 4-year follow-up.
Two-year results from a Randomized Comparison of Everolimus-Eluting and
Sirolimus-Eluting Stents in Patients Treated with Percutaneous Coronary
Intervention (SORT OUT IV Trial)
Lisette Okkels Jensen, Per Thayssen, Henrik S. Hansen, Evald H. Christiansen,
Michael Maeng, Hans-Henrik Tilsted, Anders Junker, Jan Ravkilde, Anne Kaltoft,
Morten Madsen, Henrik T. Soerensen, Leif Thuesen, Jens F. Lassen
Background: The sirolimus-eluting stent has demonstrated the least amount of late
lumen loss among previously released drug-eluting stents, but its long-term safety and
efficacy have not been compared head-to-head with the next-generation everolimus-
eluting stent
Methods: The Scandinavian Organization for Randomized Trials with Clinical
Outcome (SORT OUT) IV was a randomized multicenter, open-label, all-comer, two-
arm, non-inferiority trial comparing the everolimus-eluting stent with the
sirolimus-eluting stent in patients with coronary artery disease. The primary end point
was a composite of safety (cardiac death, myocardial infarction, definite stent
thrombosis) and efficacy (target vessel revascularization) parameters. Intention-to-treat
analyses were done at 9-month (primary end point) and two-year follow-up.
Results: 1,390 patients were assigned to receive the everolimus-eluting stent, and 1,384
patients were assigned to receive the sirolimus-eluting stent. At 9-month follow-up,
68 [4.9%] patients treated with the everolimus-eluting stent versus 72 [5.2%] patients
treated with the sirolimus-eluting stent experienced the primary end point (hazard ratio
(HR) = 0.94; 95% confidence interval (CI): 0.67 to 1.31) (p for non-inferiority = 0.01).
Two-year results will be available at the presentation.
Conclusion: Two-year results will be available at the presentation. 
Clinical Evaluation of the IN.PACT Drug-eluting Balloon for Treatment of
Femoro-popliteal Arterial Disease: Twelve Month Results from a Multicenter
Italian Registry
Antonio Micari, Angelo Cioppa, Giuseppe Vadalà, Fausto Castriota, Alberto
Cremonesi, Armando Liso, Alfredo Marchese, Chiara Grattoni, Paolo Pantaleo,
Paolo Rubino, Giancarlo Biamino
Background: This study evaluated the use of a drug-eluting balloon (DEB) for
treatment of femoropoliteal arterial disease.Conventional balloon angioplasty and
stenting in this setting is associated with a high restenosis rates within
12 months post-procedure. Recent data suggest that use of DEBs may reduce
restenosis. Twelve month outcomes following DEB use with provisional stenting are
described.
Methods: This prospective registry enrolled patients (Rutherford class 2, 3, or 4) with
reference vessel diameter of 3 to
7 mm and lesion/occlusion length ≤15 cm. Endpoints included primary patency rate,
target lesion revascularization (TLR), and changes in Rutherford class and ankle-
brachial index (ABI). Walking capacity, absolute claudication distance (ACD), and
quality of life (QOL) were also assessed
Results: At 12 months follow-up, 92/105 patients (87.6%) were evaluable. Baseline
ABI was 0.56 ± 0.15. Baseline Rutherford classification was 26.7% for class 2 and
64.8% for class 3. Most lesions were located in the superficial femoral artery (77.1%).
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Mean lesion length was 76.3 ± 38.3 mm; 29.8% of lesions were total occlusions. The
device was successfully utilized in all patients and only 12.3% of lesions required
stenting. At 12 months the primary patency rate was 83.7%, the TLR rate was 7.6%,
85.6% of patients were Rutherford class 0 or 1, and the mean ABI was 0.86 ± 0.15.
QOL and ACD significantly improved post procedure.
Conclusion: Use of a DEB for treatment of femoropopliteal arterial disease resulted
in consistent clinical improvement across multiple endpoints with a low rate of stenting
and TLR.
Efficacy and Safety of Bivalirudin Compared to Unfractionated Heparin
Among Patients Undergoing Balloon Aortic Valvuloplasty: a Two-Center
Registry.
George Dangas, Annapoorna Kini, Jennifer Yu, Mauricio Cohen, Brian O’Neill,
Shyam Poludasu, Christopher Varughese, Evan Jacobs, David Knopf, Vikas Singh,
Jason Kovacic, Robert Pyo, Pedro Moreno, Usman Baber, Roxana Mehran, Samin
Sharma
Background: With transcatheter aortic valve replacement (TAVR) on the horizon,
balloon aortic valvuloplasty (BAV) procedures have increased. A major limitation of
both BAV and TAVR is vascular and bleeding complications, with 30- day rates of
11.0% and 9.3% respectively following TAVR reported in the recent PARTNER trial.
This is partially due to the patient population, and the large caliber arterial access needed
for these procedures. Bivalirudin (BIV) has been shown to reduce bleeding
complications compared to unfractionated heparin (UFH) after PCI. Furthermore, the
“preclosure” technique with a suture-based closure device (VCD) has been reported to
achieve hemostasis after procedures with large caliber arterial sheaths. Clinical outcomes
with BIV, UFH and VCD in BAV procedures have not been previously reported. We
therefore aimed to evaluate the safety and feasibility of BIV vs. UFH in BAV.
Methods: We identified 508 consecutive pts undergoing BAV at 2 tertiary referral
centers. All pts were identified from 1/1/2005 to 12/31/2010. Baseline, clinical, and
angiographic data were extracted by an independent team. All major cardiovascular and
bleeding events were identified, source documented, and adjudicated by an independent
CEC. Clinical follow up was performed up to 30-days post procedure. All emergent
BAV procedures were excluded. Univariate and multivariate logistic regression models
were used to evaluate associations between baseline characteristics, BIV vs. UFH use,
and VCD vs. manual compression use, in reference to in-hospital and 30-day outcomes.
The primary endpoint of the study was incidence of BARC ≥3 bleeding. Major
secondary endpoints included: MACE, stroke, CV and all-cause mortality, as well as
bleeding scales according TIMI major/minor, and VARC definitions.
Results: Complete data on all consecutive patients according to BIV and VCD will be
available for presentation. 
Conclusion: This two center registry comprises the largest clinical data on BAV with BIV
and the first report of BARC, VARC, and TIMI bleeding scale comparison in this arena.
One-Year Outcomes after Implantation of XIENCE PRIME and XIENCE
PRIME Long Lesion stents in Patients with Coronary Artery Disease: Primary
Endpoint Results of the SPIRIT PRIME Multicenter Clinical Trial
Marco A. Costa, Manejeh Yaqub, Dean J. Kereiakes, Robert S. Smith, Xiaohe Yu,
Janah Aji, Louis A. Cannon, John C. Wang, Charles Simonton, Poornima Sood,
Krishnankutty Sudhir2
Background: The XIENCE V everolimus-eluting stent (EES, Abbott Vascular, Santa
Clara, CA) demonstrated superior efficacy and long term safety in the SPIRIT clinical
trials series. The next generation XIENCE PRIME EES includes
2.25 mm diameters and 33 and 38 mm lengths to treat small vessels and long lesions
(LL). The SPIRIT PRIME trial aimed to show clinical equivalence of the XIENCE
PRIME and XIENCE V stents.
Methods: SPIRIT PRIME, a prospective, non-randomized clinical trial with two
separate arms, tested the XIENCE PRIME core sizes and LL (33 and 38 mm) stents.
The primary endpoint is 1-year target lesion failure (TLF; cardiac death, target vessel
myocardial infarction [TV-MI] or clinically indicated target lesion revascularization
[CI-TLR]) compared to pre-specified performance goals based on historical data
according to FDA requirements. The Core Size Registry (CSR) analyzed 401 patients
and the Long Lesion Registry (LLR) 104 patients. Treatment of up to 2 de novo lesions
in different epicardial vessels was allowed. Data were fully monitored and all endpoint
events adjudicated by an independent committee.
Results: There were 447 CSR and 124 LLR lesions treated and a total of 530 XIENCE
PRIME and 105 XIENCE PRIME LL stents implanted. Clinical device success rates
were 98.2% (CSR) and 97.6% (LLR). Female and diabetic subjects were 29.7% and
34.9%, respectively in the CSR and 37.5% and 35.6%, respectively in the LLR. In both
arms, the primary endpoint was met by all analyses. The Table shows 1-year outcomes.
Conclusion: The SPIRIT PRIME study demonstrated 1-year safety and efficacy of the
new XIENCE PRIME EES with low cardiac death, MI and CI-TLR rates in core size
and LL cohorts, suggesting clinical equivalence of the XIENCE PRIME stent to
XIENCE V.
SeQuent Please World Wide Registry: Paclitaxel eluting balloon angioplasty in
routine real world practice in a large patient population
Jochen Wöhrle 
Background: The paclitaxel eluting SeQuent Please balloon catheter (B.Braun
Melsungen AG, Germany) has shown to be superior to plain balloon angioplasty for
treatment of in-stent restenosis (ISR) in bare-metal stents (BMS) and in drug-eluting
stents (DES). Furthermore, paclitaxel eluting balloon angioplasty reduced angiographic
and clinical restenosis in de-novo lesions after endothelial progenitor cell capturing
stenting. However, in these trials number of patients was limited and inclusion criteria
were restricted to a pre-defined lesion subset.
Therefore, we performed the SeQuent Please World Wide Registry in order to get the
results of paclitaxel eluting balloon angioplasty in a large sized registry without
limitation to a special patient population.
Methods: 2098 patients with 2359 lesions treated with SeQuent Please paclitaxel
eluting balloon angioplasty were included in 75 centres from 8 countries. Patients are
clinically followed. The primary endpoint is the clinically driven target lesion
revascularization rate (TLR) at 9 month. Secondary clinical endpoints are target vessel
revascularization, vessel thrombosis according to ARC criteria, major adverse cardiac
events as a composite of cardiac death, TLR and myocardial infarction related to the
target vessel.
Results: Patients were included due to treatment of ISR in BMS (38%), ISR in DES
(23%), ISR in DES/BMS (10%) or de-novo lesions (29%). Patients suffered from
STEMI/NSTEMI in 17% and from unstable angina in 39%. Frequency of diabetes
mellitus was high with 35%. Treatment location included LAD (40%), CX artery
(24%), RCA (31%) but also saphenous vein grafts (5%). Balloon length ranged from
10-30mm, balloon diameter from 2.0-4.0mm. Antiplatelet therapy with aspirin was
mainly combined with clopidogrel (96%) but also with prasugrel (4%) and ranged from
3-12 months. Nine months follow-up will be completed in September 2011.
Conclusion: Clinical 9 months data including the primary endpoint (clinically driven
TLR) will be presented for the first time.
The Mechanism Of Stent Thrombosis (MOST) study.
Guido Parodi, Alessio La Manna, Marco Valgimigli, Massimo Fineschi, Vito
Ramazzotti, Benedetta Bellandi, Giampaolo Niccoli, Renato Valenti, David
Antoniucci, Francesco Prati
Background: Stent thrombosis (ST) may occur late after stent implantation, and its
cause remains unknown. The use of Optical Coherence Tomography (OCT) in patients
with ST is a valid approach to understand the impact of stent related features that can
lead to ST. We sought to assess by OCT stent strut coverage and malapposition after
thrombectomy in consecutive patients presenting with ST.
Methods: The Mechanism Of Stent Thrombosis (MOST) Study was a prospective
multicentre non-randomized registry that enrolled 23 (6 subacute, and 17 late or very
late) ST patients between January 2010 and July 2011. The included patients were
matched (1:1) with control subjects who had OCT stent assessment at the same Core
Lab, during the same time period, at the same time interval from stent implantation.
Blinded OCT analyses were done in all cases in a validated core lab (RHR, Rome). The
2 study groups were similar in all the baseline characteristics.
Results: Overall, 16,367 and 13,047 struts were analysed in the ST and in the matched
group, respectively. Patients with ST showed a higher rate of uncovered and
malapposed struts as compared with the control group (table). All patients with ST had
previously discontinued dual antiplatelet therapy (n=14) or showed high residual
platelet reactivity on clopidogrel therapy.
Conclusion: Patients with stent thrombosis showed a higher rate of uncovered and
malapposed stent struts as compared with control subjects. High platelet reactivity
seems a necessary co-factor.
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